UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
Abstract Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full “lay” summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
BMC nephrology - 24(2023), 1 vom: 25. Okt. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Roddick, Alistair J. [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
Anmerkungen: |
© The Author(s) 2023 |
---|
doi: |
10.1186/s12882-023-03339-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR053524357 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR053524357 | ||
003 | DE-627 | ||
005 | 20231120064728.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231026s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12882-023-03339-3 |2 doi | |
035 | |a (DE-627)SPR053524357 | ||
035 | |a (SPR)s12882-023-03339-3-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Roddick, Alistair J. |e verfasserin |4 aut | |
245 | 1 | 0 | |a UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Abstract Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full “lay” summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals. | ||
650 | 4 | |a Guideline |7 (dpeaa)DE-He213 | |
650 | 4 | |a Chronic kidney disease |7 (dpeaa)DE-He213 | |
650 | 4 | |a Acute kidney injury |7 (dpeaa)DE-He213 | |
650 | 4 | |a Gliflozin |7 (dpeaa)DE-He213 | |
700 | 1 | |a Wonnacott, Alexa |4 aut | |
700 | 1 | |a Webb, David |4 aut | |
700 | 1 | |a Watt, Angela |4 aut | |
700 | 1 | |a Watson, Michael A. |4 aut | |
700 | 1 | |a Staplin, Natalie |4 aut | |
700 | 1 | |a Riding, Alex |4 aut | |
700 | 1 | |a Lioudaki, Eirini |4 aut | |
700 | 1 | |a Kuverji, Apexa |4 aut | |
700 | 1 | |a Kossi, Mohsen El |4 aut | |
700 | 1 | |a Holmes, Patrick |4 aut | |
700 | 1 | |a Holloway, Matt |4 aut | |
700 | 1 | |a Fraser, Donald |4 aut | |
700 | 1 | |a Carvalho, Chris |4 aut | |
700 | 1 | |a Burton, James O. |4 aut | |
700 | 1 | |a Bhandari, Sunil |4 aut | |
700 | 1 | |a Herrington, William G. |4 aut | |
700 | 1 | |a Frankel, Andrew H. |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC nephrology |d London : BioMed Central, 2000 |g 24(2023), 1 vom: 25. Okt. |w (DE-627)SPR027503283 |w (DE-600)2041348-8 |x 1471-2369 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:25 |g month:10 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12882-023-03339-3 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 24 |j 2023 |e 1 |b 25 |c 10 |